<DOC>
	<DOC>NCT01277627</DOC>
	<brief_summary>Nevirapine-based antiretroviral therapy is associated with lower plasma HCV viral load in HIV/HCV-coinfected individuals.</brief_summary>
	<brief_title>Influence of Nevirapine on HCV Viral Load</brief_title>
	<detailed_description />
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>HIV infection. Older than 18 years. Chronic hepatitis C. Undetectable HIV viral load during one year before starting study. To have not received HCV therapy during one year before starting study. To have not started efavirenz or protease inhibitors o nucleoside analogs during 6 months before starting study. Non contraindications for drugs included in this study. To change an antiretroviral regimen including efavirenz or protease inhibitors by nevirapine due to side effects, interactions or pregnancy (NVP group) To continue with a antiretroviral regimen including efavirenz or protease inhibitors (nonNVP group) Both groups will be matched according to these variables: Liver stiffness. HCV genotype. Hospital. Time from starting antiretroviral therapy. Previous third drug (EFV or PI) to introduction of NVP. HCV therapy during followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>HCV</keyword>
	<keyword>HIV</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>HCV viral load</keyword>
	<keyword>Efavirenz</keyword>
	<keyword>Protease inhibitors</keyword>
</DOC>